[
  {
    "pmid": "40650712",
    "citation": "Carlos Jiménez-Vicente et al. Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.. Annals of hematology (2025 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40650712/",
    "drug": "azacitidine",
    "complete_response": 26.1,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 39.1,
    "progression_free_survival_median": null,
    "overall_survival_median": 8.3,
    "total_patients": 23,
    "cmml_patients": null,
    "supporting_quotes": [
      "The median number of cycles administered was four, with an overall response rate (ORR) of 39.1% and a morphological complete remission (CR) rate of 26.1%.",
      "Median overall survival (OS) was 8.3 months.",
      "Patients who achieved a complete response had a better outcome than the rest of the patients in terms of OS (19.8 months (95%CI: 15.7-NR) vs. 4.2 (95%CI: 1.5-NR), p = 0.01)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reported an overall response rate of 39.1% and a complete response rate of 26.1%. Median overall survival was 8.3 months.  Patients achieving complete response had significantly longer survival (19.8 months) compared to non-responders (4.2 months).  The number of CMML patients was not explicitly stated.",
    "has_efficacy_data": true
  },
  {
    "pmid": "40252309",
    "citation": "Julie S Braish et al. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome.. Leukemia research (2025 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40252309/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 49.0,
    "progression_free_survival_median": 6.0,
    "overall_survival_median": 7.0,
    "total_patients": 33,
    "cmml_patients": null,
    "supporting_quotes": [
      "The ORR was 49 %, and the median overall survival (OS) was 7 months (95 % CI, 3.5-10.5).",
      "The median progression-free survival (PFS) was 6 months (95 % CI, 3.0-9.0).",
      "This Phase I/II study evaluates the safety, tolerability, and efficacy of venetoclax, an orally bioavailable BCL-2 inhibitor, in combination with azacitidine in this population. We conducted a single-center, dose-escalation, Phase I/II trial (NCT04550442) involving 33 patients with HR-MDS or CMML (IPSS ≥ 1.5) who had progressed after prior HMA therapy."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 49%, with median progression-free survival and overall survival of 6 and 7 months, respectively.  The number of CMML patients specifically was not explicitly stated.",
    "has_efficacy_data": true
  },
  {
    "pmid": "40164584",
    "citation": "Alex Bataller et al. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study.. Blood cancer journal (2025 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/40164584/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 90.0,
    "progression_free_survival_median": 18.0,
    "overall_survival_median": 24.0,
    "total_patients": 124,
    "cmml_patients": 20,
    "supporting_quotes": [
      "The overall response rate was superior in the DEC-C-Ven cohort (90% vs 64%, P = 0.002).",
      "The median overall survival was 24 and 19 months for the DEC-C-Ven and DEC-C cohorts, respectively (P = 0.89), and the median event-free survival durations were 18 and 10 months (P = 0.026).",
      "The DEC-C and DEC-C-Ven cohorts had 73 and 51 patients respectively, resulting in a total of 124 patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The addition of venetoclax to decitabine-cedazuridine resulted in a significantly higher overall response rate (90% vs 64%) and a longer median progression-free survival (18 months vs 10 months) in patients with MDS or CMML.  Overall survival difference was not statistically significant (24 months vs 19 months).",
    "has_efficacy_data": true
  },
  {
    "pmid": "38387931",
    "citation": "Xiao Li et al. [Clinical Efficacy of Hypomethylating Agent Therapy in Patients with Chronic Myelomonocytic Leukemia].. Zhongguo shi yan xue ye xue za zhi (2024 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38387931/",
    "drug": "azacitidine",
    "complete_response": 28.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 80.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 17.4,
    "total_patients": 25,
    "cmml_patients": 25,
    "supporting_quotes": [
      "Among them, 20 patients responded, and 7 patients got complete remission (CR).",
      "All patients with CR were treated with DEC as the basic treatment.",
      "After a median follow-up of 16.4 (9.4-20.5) months, 4 patients with CR progressed to acute myeloid leukemia (AML).",
      "The median overall survival (OS) time of 25 CMML patients was 17.4 months"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an 80% overall response rate with a 28% complete remission rate in 25 CMML patients treated with hypomethylating agents. Median overall survival was 17.4 months.  Progression to AML was observed in some patients achieving CR.",
    "has_efficacy_data": true
  },
  {
    "pmid": "38091231",
    "citation": "Kensuke Usuki et al. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).. International journal of hematology (2024 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/38091231/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 6568,
    "cmml_patients": 182,
    "supporting_quotes": [
      "From August 2011 to January 2016, we enrolled 6568 patients.",
      "Herein, we report the results for ... CMML (n = 182).",
      "The estimated overall survival (OS) rate at 5 years were ... 15.0% (8.9-22.7%) for CMML."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study provides overall survival (OS) rate at 5 years for CMML patients (15.0%, with a range of 8.9-22.7%).  No other response rates or survival metrics (e.g., PFS) were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "37548390",
    "citation": "Lisa Pleyer et al. Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMT.. American journal of hematology (2023 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37548390/",
    "drug": "azacitidine",
    "complete_response": 17.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 26.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 22.8,
    "total_patients": 1441,
    "cmml_patients": 132,
    "supporting_quotes": [
      "Adjusted median overall survival for patients achieving PB-CR was 22.8 months (95%CI 18.9-26.2) versus 10.4 months (95%CI 9.7-11.2) for those who did not; HR = 0.366 (95%CI 0.303-0.441; p < .0001).",
      "Among patients achieving CR, those additionally achieving PB-CR had a median adjusted OS of 32.6 months (95%CI 26.2-49.2) versus 21.7 months (95%CI 16.9-27.7; HR = 0.400 [95%CI 0.190-0.844; p = .0161]) for those who did not.",
      "1441 patients were included: MDS (n = 522; 36.2%), CMML (n = 132; 9.2%), or AML (n = 787; 54.6%).",
      "Of the 699 of 1441 (49%) patients in whom a BM evaluation was performed during treatment with azacitidine, a CR was observed in 17% and a CRi in an additional 9%.",
      "Hematologic improvement was observed in 43% of patients, and 13% of patients achieved PB-CR after a median of 4.6 (IQR 2.8-6.7) months.",
      "Median duration of PB-CR was 7.0 (IQR 1.9-15.6) months.",
      "Of 119 patients who achieved PB-CR and who had a concomitant BM evaluation, 88 (74.0%) had a CR, 12 (1.0%) had a PR, 19 (1.6%) had a stable disease in the BM."
    ],
    "data_source_location": "full_manuscript",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a median overall survival of 22.8 months for patients achieving peripheral blood complete remission (PB-CR), compared to 10.4 months for those who did not. Among patients achieving morphologic CR, those additionally achieving PB-CR had significantly longer survival (32.6 vs 21.7 months). The study included 1441 patients (132 CMML), with 17% CR rate and 26% overall response rate (CR+CRi). PB-CR was achieved by 13% of patients and was associated with 74% concordance with morphologic CR.",
    "has_efficacy_data": true,
    "additional_data": {
      "study_design": "Prospective cohort study from Austrian Myeloid Registry (aMYELOIDr)",
      "pb_cr_definition": {
        "peripheral_blood_blasts": "0%",
        "absolute_neutrophil_count": "≥1.0 × 10³/μL",
        "white_blood_cell_count": "≥1.5 × 10³/μL and <10.0 × 10³/μL",
        "monocytes": "≤1.0 × 10³/μL",
        "hemoglobin": "≥11.0 g/dL",
        "platelet_count": "≥100 × 10³/μL and <450 × 10³/μL",
        "transfusion_independence": "Red blood cell and platelet",
        "growth_factors": "No treatment with growth factors",
        "duration": "≥8 weeks"
      },
      "response_rates": {
        "complete_remission": "17%",
        "cri_rate": "9%",
        "overall_response": "26%",
        "hematologic_improvement": "43%",
        "pb_cr_rate": "13%"
      },
      "survival_data": {
        "pb_cr_achieved_os": "22.8 months (95%CI 18.9-26.2)",
        "pb_cr_not_achieved_os": "10.4 months (95%CI 9.7-11.2)",
        "hazard_ratio": "0.366 (95%CI 0.303-0.441)",
        "risk_reduction": "63%",
        "cr_with_pb_cr_os": "32.6 months (95%CI 26.2-49.2)",
        "cr_without_pb_cr_os": "21.7 months (95%CI 16.9-27.7)"
      },
      "treatment_details": {
        "median_cycles": "5.0 (IQR 2.0-12.0)",
        "cmml_median_cycles": "8.0 (IQR 4.0-16.5)",
        "treatment_days_per_cycle": "7 (IQR 5-7)",
        "median_dose_per_cycle": "875 mg (IQR 700-1000)",
        "pb_cr_time_to_achievement": "4.6 months (IQR 2.8-6.7)",
        "pb_cr_duration": "7.0 months (IQR 1.9-15.6)"
      },
      "bm_evaluation_data": {
        "patients_with_bm_eval": "699 (49%)",
        "pb_cr_bm_concordance": {
          "complete_remission": "88 (74.0%)",
          "partial_response": "12 (1.0%)",
          "stable_disease": "19 (1.6%)",
          "progressive_disease": "0 (0.0%)"
        }
      }
    }
  },
  {
    "pmid": "37422688",
    "citation": "Nicholas J Short et al. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.. Journal of hematology & oncology (2023 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37422688/",
    "drug": "azacitidine",
    "complete_response": 50.0,
    "partial_response": null,
    "marrow_complete_response": 50.0,
    "overall_response_rate": 75.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 8.1,
    "total_patients": 40,
    "cmml_patients": 8,
    "supporting_quotes": [
      "In the AML cohort, ... the CR/CRi rate was 66% (CR 50%; CRi 16%), and the median overall survival (OS) was 8.1 months.",
      "In the MDS/CMML cohort, ... The overall response rate was 75% (CR 13%; mCR with or without HI 50%; HI 13%).",
      "Forty patients were enrolled (32 with AML and 8 with MDS/CMML)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In the AML cohort, a 50% complete response rate and 8.1-month median overall survival were observed.  The MDS/CMML cohort showed a 75% overall response rate, with 13% complete response and 50% marrow complete response.",
    "has_efficacy_data": true
  },
  {
    "pmid": "37042080",
    "citation": "Raoul Tibes et al. Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.. Cancer (2023 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/37042080/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 62,
    "cmml_patients": null,
    "supporting_quotes": [
      "Sixty-two patients (28 [45%] newly diagnosed) were treated in this study",
      "Out of 21 rrAML patients, two achieved response (one complete response/one morphologic leukemia-free state) with no responses seen in seven r/r MDS/CMML patients.",
      "In newly diagnosed AML/MDS, response was seen in six (three had complete remission, two had morphological leukemia-free status) of 27 patients.",
      "Median overall survival was 26.4 and 4.7 months for newly diagnosed MDS and AML, respectively."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study showed limited response rates in patients with myeloid neoplasms, including  no response in seven patients with refractory/relapsed MDS/CMML.  Overall survival varied greatly depending on the diagnosis (26.4 months for newly diagnosed MDS vs 4.7 months for newly diagnosed AML). Specific response rates (CR, PR, ORR) for CMML were not reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "36282401",
    "citation": "Julia Reiser et al. Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.. Wiener medizinische Wochenschrift (1946) (2023 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/36282401/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 23.0,
    "total_patients": 168,
    "cmml_patients": 168,
    "supporting_quotes": [
      "In a retrospective observational study, we analyzed 168 CMML patients regarding treatment options and survival during the past three decades.",
      "Median overall survival (OS) increased from 10 months before 2000 to 23 months thereafter (p = 0.021).",
      "AZA-treated patients but not patients treated with other treatment options had improved survival as compared to CMML patients without AZA therapy (19 vs. 25 months, p = 0.041)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an increase in median overall survival from 10 months to 23 months over three decades.  Azacitidine (AZA) treatment was associated with improved survival (19 vs 25 months), particularly in subgroups with Hb >10 g/dL, monocytosis >10 G/L, and RASopathy gene mutations.",
    "has_efficacy_data": true
  },
  {
    "pmid": "35834039",
    "citation": "Yu Xu et al. Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.. Investigational new drugs (2022 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35834039/",
    "drug": "azacitidine",
    "complete_response": 8.3,
    "partial_response": 8.3,
    "marrow_complete_response": 20.8,
    "overall_response_rate": 37.5,
    "progression_free_survival_median": null,
    "overall_survival_median": 23.0,
    "total_patients": 24,
    "cmml_patients": 24,
    "supporting_quotes": [
      "Overall response rate (ORR) was 37.5% (9 of 24); CR rate, PR rate, and mCR/HI rate were 8.3% (n = 2), 8.3% (n = 2), and 20.8% (n = 5), respectively.",
      "At a median duration of follow-up of 14.0 months (range 0.0-22.0 months), the median overall survival (OS) was 23.0 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Azacitidine treatment showed an overall response rate of 37.5% in a study of 24 CMML patients.  Complete response, partial response, and marrow complete response rates were 8.3%, 8.3%, and 20.8%, respectively. Median overall survival was 23 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "35488900",
    "citation": "Mikkael A Sekeres et al. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.. Annals of hematology (2022 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35488900/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 33.3,
    "progression_free_survival_median": null,
    "overall_survival_median": 15.8,
    "total_patients": 72,
    "cmml_patients": null,
    "supporting_quotes": [
      "Overall response rates in the AML and MDS cohorts were 30.0% and 33.3%, respectively",
      "Median overall survival (95% confidence interval) was 9.2 (6.2-14.0) months and 15.8 (9.3-21.9) months, respectively"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 33.3% in the MDS cohort (which includes CMML patients), and a median overall survival of 15.8 months in the same cohort.  The exact number of CMML patients is not specified.",
    "has_efficacy_data": true
  },
  {
    "pmid": "35438802",
    "citation": "Lionel Adès et al. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's \"pick a winner\" trial, with the impact of somatic mutations.. British journal of haematology (2022 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35438802/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 21.4,
    "progression_free_survival_median": 17.2,
    "overall_survival_median": 19.7,
    "total_patients": 322,
    "cmml_patients": null,
    "supporting_quotes": [
      "After six cycles, 69 (21.4%) CR + PR were observed with no benefit from any combination.",
      "Median EFS and OS were 17.2 and 19.7 months in the whole cohort, respectively, with no difference across randomised arms.",
      "322 patients were included."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 21.4% after six cycles of treatment.  Median progression-free survival was 17.2 months, and median overall survival was 19.7 months. No significant benefit was observed from any combination therapy compared to azacitidine alone.",
    "has_efficacy_data": true
  },
  {
    "pmid": "35405632",
    "citation": "A Triguero et al. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.. Leukemia research (2022 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/35405632/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 58.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 91,
    "cmml_patients": 91,
    "supporting_quotes": [
      "The overall response rate at cycle 4-6 was 58%",
      "We retrospectively studied 91 patients with CMML treated with at least one cycle of AZA from the Spanish Registry of MDS."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study shows an overall response rate of 58% at cycles 4-6 in 91 CMML patients treated with azacitidine.  No data on complete response, partial response, marrow complete response, progression-free survival, or overall survival was provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34985762",
    "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.. American journal of hematology (2022 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34985762/",
    "drug": "azacitidine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 47.5,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ~40%-50% and complete remission rates of ~7%-17%; with no impact on mutational allele burdens."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The abstract reports overall response rates of approximately 47.5% (midpoint of 40-50%) for hypomethylating agents like 5-azacitidine and decitabine, and complete remission rates of approximately 7-17%.  No survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34884286",
    "citation": "Marion Delplanque et al. USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still's Disease in Elderly Patients.. Journal of clinical medicine (2021 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34884286/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 83.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 30.0,
    "total_patients": 26,
    "cmml_patients": null,
    "supporting_quotes": [
      "A French multicenter retrospective study from the MINHEMON study group also used for other published works with the support of multidisciplinary and complementary networks of physicians and a control group of 104 MDS/CMML. Twenty-six patients were included with a median age at first signs of USAID of 70.5 years with male predominance (4:1).",
      "Azacytidine resulted in complete or partial response in systemic symptoms for 10/12 (83%) patients including 3 VEXAS.",
      "Twelve died during a median follow-up of 2.5 years"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 85,
    "efficacy_summary": "The study reports an 83% overall response rate to azacytidine for systemic symptoms in 10 out of 12 patients.  The median overall survival was 30 months (2.5 years).  Specific response rates (complete, partial, marrow complete) were not reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34384334",
    "citation": "Krzysztof Mądry et al. Low serum albumin level deteriorates prognosis in azacitidine-treated myelodysplastic syndromes patients - results of the PALG study 'PolAZA'.. Hematology (Amsterdam, Netherlands) (2021 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34384334/",
    "drug": "azacitidine",
    "complete_response": 20.0,
    "partial_response": 12.0,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 15.0,
    "total_patients": 315,
    "cmml_patients": null,
    "supporting_quotes": [
      "Complete remission (CR) was obtained in 20% and partial remission (PR) in 12% of patients.",
      "Median survival was 15 (13-19) months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a 20% complete response rate and a 12% partial response rate to azacitidine treatment. Median overall survival was 15 months.  The exact number of CMML patients within the study cohort is not specified.",
    "has_efficacy_data": true
  },
  {
    "pmid": "34175902",
    "citation": "Aline Renneville et al. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.. Leukemia (2021 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/34175902/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 24.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Median overall survival of this aggressive myeloid malignancy is only 2-3 years"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract mentions a median overall survival of 2-3 years (24-36 months).  No other response rates or survival data are explicitly provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33706667",
    "citation": "Ruohao Xu et al. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.. Hematology (Amsterdam, Netherlands) (2021 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33706667/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 43.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 600,
    "cmml_patients": 600,
    "supporting_quotes": [
      "HMAs yielded a pooled ORR estimate of 43% (95% CI: 36%-50%) in patients with CMML.",
      "Fourteen studies with 600 CMML patients (decitabine: n=196; azacitidine: n=404) were identified and included for meta-analysis.",
      "Patients received either azacitidine or decitabine exhibited comparable incidence of ORR (43% vs. 45%, P=0.810), while significantly higher incidence of mCR was observed in patients treated with decitabine (23% vs. 10%, P=0.000)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The meta-analysis of 600 CMML patients treated with hypomethylating agents (HMAs) showed an overall response rate (ORR) of 43%.  Decitabine showed a higher marrow complete response (mCR) rate (23%) compared to azacitidine (10%).  ORR was comparable between the two drugs.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33513373",
    "citation": "Lisa Pleyer et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.. The Lancet. Haematology (2021 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33513373/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 20.7,
    "total_patients": 949,
    "cmml_patients": 949,
    "supporting_quotes": [
      "Adjusted median overall survival for patients treated with hydroxyurea versus hypomethylating agents was 15·6 months (95% CI 13·1-17·3) versus 20·7 months (17·9-23·4); hazard ratio (HR) 1·39 (1·17-1·65; p=0·0002)",
      "412 (43%) of 949 patients received hypomethylating agents as first treatment, 391 (41%) hydroxyurea, and 83 (9%) intensive chemotherapy."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a median overall survival of 20.7 months for patients treated with hypomethylating agents, compared to 15.6 months for those treated with hydroxyurea.  Hypomethylating agents showed a survival advantage over hydroxyurea and intensive chemotherapy, particularly in higher-risk CMML patients and those with myeloproliferative CMML.  No response rates were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33324479",
    "citation": "Luka Čemažar et al. Successful long-term treatment with azacitidine in patient with chronic myelomonocytic leukemia.. Hematology reports (2020 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33324479/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 137.0,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Effective treatment with azacitidine resulted in overall survival of 11 years 5 months",
      "Our report about a patient with CMML and a good clinical course revealed, that long term treatment with azacitidine is feasible in some patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a single case of CMML successfully treated with azacitidine resulting in an overall survival of 137 months (11 years and 5 months).  No other response rates or survival metrics are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "33275673",
    "citation": "Mrinal M Patnaik et al. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.. Hematology. American Society of Hematology. Education Program (2020 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/33275673/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 45.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 36.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "CMML usually presents in the 7th decade of life, with a male preponderance and is associated with a median overall survival of <36 months.",
      "Hypomethylating agents such as azacitidine, decitabine and oral decitabine/cedazuridine have been US FDA approved for the management of CMML, with overall response rates of 40-50% and complete remission rates of <20%."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The median overall survival for CMML is less than 36 months.  Overall response rates to hypomethylating agents (azacitidine, decitabine, and oral decitabine/cedazuridine) are 40-50%, with complete remission rates less than 20%.  No data on progression-free survival,  patient numbers, or complete/partial response rates were explicitly stated.",
    "has_efficacy_data": true
  },
  {
    "pmid": "32896704",
    "citation": "Anne Laure Roupie et al. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.. Seminars in arthritis and rheumatism (2020 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32896704/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 44.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 70,
    "cmml_patients": null,
    "supporting_quotes": [
      "After a median follow-up of 33.2 months [1-162], 31 patients (44%) achieved sustained remission."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a 44% sustained remission rate after a median follow-up of 33.2 months.  No other response rates or survival data (PFS, OS) were explicitly provided.  Conventional DMARDs showed lower efficacy compared to biologics or azacytidine.",
    "has_efficacy_data": true
  },
  {
    "pmid": "32576961",
    "citation": "Arnold Kloos et al. Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia.. Leukemia (2020 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32576961/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "The novel combination treatment with azacitidine and the MEK-inhibitor trametinib additively inhibited ERK-phosphorylation and thus depleted the signal from mutated NRAS.",
      "The combination treatment significantly prolonged survival of CMML mice compared to single-agent treatment."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study demonstrates that the combination treatment of azacitidine and trametinib significantly prolonged survival in a CMML mouse model.  However, no specific response rates or survival metrics (in months) are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "32373459",
    "citation": "Celine Berthon et al. Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size.. Leukemia research reports (2020)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32373459/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": 40,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 0,
    "supporting_quotes": [
      "Both diseases first responded to treatment for 40 months after 7+3 induction and maintenance therapy of azacytidine + lenalidomide.",
      "MM relapsed first and was treated with azacytidine + daratumumab, which led an additional 15 months of progression-free survival."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports a single case of synchronous AML and MM.  Initial treatment with azacytidine + lenalidomide resulted in 40 months of response for both diseases. Following MM relapse, treatment with azacytidine + daratumumab provided an additional 15 months of progression-free survival.  No response rates were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "32285126",
    "citation": "Guillermo Garcia-Manero et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.. Blood (2020 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/32285126/",
    "drug": "azacitidine",
    "complete_response": 21.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 60.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 80,
    "cmml_patients": null,
    "supporting_quotes": [
      "Clinical responses were observed in 48 patients (60%), including 17 (21%) with complete response."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reported an overall response rate of 60%, with a complete response rate of 21%.  No partial response, marrow complete response, progression-free survival, or overall survival data were provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31870430",
    "citation": "Anastasiya Kazachenka et al. Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression.. Genome medicine (2019 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31870430/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 50.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Drugs that reverse epigenetic repression, such as 5-azacytidine (5-AZA), induce haematological improvement in half of treated patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The study mentions that 5-azacytidine induces hematological improvement in 50% of treated patients.  No other response rates or survival data are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31736132",
    "citation": "Mrinal M Patnaik et al. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.. American journal of hematology (2020 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31736132/",
    "drug": "azacitidine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 45.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ~40%-50% and complete remission rates of ~7%-17%; with no impact on mutational allele burdens."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "The abstract reports overall response rates of 40-50% and complete remission rates of 7-17% for hypomethylating agents in CMML treatment.  No other efficacy data such as survival times or patient numbers are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31559392",
    "citation": "Abhishek A Mangaonkar et al. Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics.. Advances in cell and gene therapy (2019 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31559392/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 24.0,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Outcomes remain uniformly poor with a median overall survival of ~2 years"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The abstract mentions a median overall survival of approximately 2 years (24 months).  No other efficacy data such as response rates or progression-free survival is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "31221030",
    "citation": "Chutima Kunacheewa et al. A systematic review and meta. Hematology (Amsterdam, Netherlands) (2019 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/31221030/",
    "drug": "azacitidine",
    "complete_response": 33.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 406,
    "cmml_patients": null,
    "supporting_quotes": [
      "The pooled CR rate after the treatment with AZA-plus-LEN regimen was 33.0% (95% CI, 27.7%-38.7%, I",
      "A total of 10 studies with 406 patients were identified and included into the meta-analysis."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The meta-analysis of 10 studies (406 patients) showed a pooled complete response rate of 33.0% for the AZA-plus-LEN regimen.  No other response rates or survival data were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "30964202",
    "citation": "Tucker Coston et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.. American journal of hematology (2019 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30964202/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 41.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 31.0,
    "total_patients": 121,
    "cmml_patients": 121,
    "supporting_quotes": [
      "The overall response rates were 41% by the IWG MDS (AZA- 45%, DAC-39%), and 56% by the IWG MDS/MPN (AZA-56%, DAC-58%) response criteria, with CR (complete remission) rates of <20% for both agents, by both criteria.",
      "HMA treated patients had a longer median OS (31 vs 18 months; P = .01), in comparison to those treated with conventional care regimens (excluding observation only patients), without any differences between AZA vs DAC (P = .37)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Overall response rates to hypomethylating agents (HMAs) in CMML patients were 41% (IWG MDS criteria) and 56% (IWG MDS/MPN criteria). Complete response rates were less than 20%. Median overall survival was 31 months for patients treated with HMAs, compared to 18 months for those treated with conventional care.  Progression after HMA response was associated with a median overall survival of 8 months, while median OS in patients with primary HMA failure was 4 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "30613922",
    "citation": "Grzegorz Helbig et al. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.. Pathology oncology research : POR (2019 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30613922/",
    "drug": "azacitidine",
    "complete_response": 10.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 20.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 83,
    "cmml_patients": 10,
    "supporting_quotes": [
      "Complete remission (CR) was achieved in 14% of MDS, 7% of AML and 10% of CMML patients.",
      "Overall response rate was following: 27% for MDS, 20% for AML and 20% for CMML.",
      "The study included 83 patients (65% male) with a median age at diagnosis of 68 years. 43 patients were diagnosed with higher-risk MDS, 30 had AML and 10-CMML."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine showed limited efficacy in CMML patients with a 10% complete response rate and a 20% overall response rate.  Overall survival at 12 months was 75%.  Median follow-up was 9.4 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "30424699",
    "citation": "Panagiotis T Diamantopoulos et al. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.. Leukemia & lymphoma (2019 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30424699/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 48.9,
    "progression_free_survival_median": null,
    "overall_survival_median": 29.7,
    "total_patients": 88,
    "cmml_patients": 88,
    "supporting_quotes": [
      "The overall response rate was 48.9% and the median overall survival (OS) 29.7 months.",
      "We analyzed the characteristics of 88 patients with CMML homogeneously treated with 5-azacytidine (Hellenic 5-Azacytidine Registry)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study shows an overall response rate of 48.9% and a median overall survival of 29.7 months in 88 CMML patients treated with 5-azacytidine.",
    "has_efficacy_data": true
  },
  {
    "pmid": "30091166",
    "citation": "Jürgen Wehmeyer et al. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study).. European journal of haematology (2018 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30091166/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 45.9,
    "progression_free_survival_median": 10.9,
    "overall_survival_median": 14.1,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "45.9% of patients showed CR or PR.",
      "Median PFS was 10.9 months.",
      "Median OS was 14.1 months.",
      "61.1% of patients were diagnosed with MDS, 31.5% with AML and 7.4% with CMML."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In the PIAZA study, azacitidine treatment resulted in a 45.9% overall response rate (CR/PR). Median progression-free survival was 10.9 months, and median overall survival was 14.1 months.  The study did not provide separate CR and PR rates, nor the total number of patients or the number of CMML patients.",
    "has_efficacy_data": true
  },
  {
    "pmid": "30016552",
    "citation": "Michael R Savona et al. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.. American journal of hematology (2018 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30016552/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 32.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 31,
    "cmml_patients": 4,
    "supporting_quotes": [
      "Overall response rate (complete remission [CR], CR with incomplete hematological recovery [CRi], partial remission [PR], marrow CR) in the MDS/CMML subgroups was 32% and in the AML subgroup (CR/CRi/PR) was 22%",
      "After a pharmacokinetic assessment period, 31 patients (MDS n = 18, CMML n = 4, and AML n = 9) entered a clinical phase"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 32% in the MDS/CMML patient subgroup.  No breakdown of individual response rates (CR, PR, mCR) was provided for the CMML patients specifically, only the combined MDS/CMML group.",
    "has_efficacy_data": true
  },
  {
    "pmid": "29878489",
    "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.. American journal of hematology (2018 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29878489/",
    "drug": "azacitidine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 35.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ∼30%-40% and complete remission rates of ∼7%-17%; with no impact on mutational allele burdens."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "Hypomethylating agents such as 5-azacitidine and decitabine show an overall response rate of approximately 35% (median of the provided range), with a complete remission rate of approximately 7-17%.  No survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "29728305",
    "citation": "Matthieu Duchmann et al. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.. EBioMedicine (2018 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29728305/",
    "drug": "azacitidine",
    "complete_response": 17.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 52.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 174,
    "cmml_patients": 174,
    "supporting_quotes": [
      "Overall response rate (ORR) was 52%, including complete response (CR) in 28 patients (17%)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reported an overall response rate of 52% with a complete response rate of 17% in a cohort of 174 CMML patients treated with hypomethylating agents.  No data on partial response, marrow complete response, progression-free survival, or overall survival was provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "29069007",
    "citation": "Yayue Gao et al. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.. Medicine (2017 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/29069007/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 2,
    "cmml_patients": 2,
    "supporting_quotes": [
      "In both patients, the platelet counts returned to the normal within 1 week after eltrombopag therapy.",
      "The platelet count in case 1 patient remained stable at 141-200 × 10/L for 20 months with stopping therapy for 3 months.",
      "In case 2 patient, eltrombopag was stopped 1 month later. Her platelet count decreased to 41 × 10/L, but was stable at ∼30 × 10/L for 3 months with platelet transfusion independency for 12 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Both patients with CMML and thrombocytopenia showed a rapid increase in platelet counts after eltrombopag treatment.  Case 1 maintained stable platelet counts for 20 months with a 3-month treatment interruption, and case 2 remained transfusion-independent for 12 months after a period of lower platelet counts following eltrombopag discontinuation.",
    "has_efficacy_data": true
  },
  {
    "pmid": "28621841",
    "citation": "Amer M Zeidan et al. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.. Cancer (2017 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28621841/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 13,
    "total_patients": 1378,
    "cmml_patients": 1378,
    "supporting_quotes": [
      "Among 1378 older adults diagnosed with CMML, the median OS was 13 months",
      "In the primary matched analysis, with 225 HMA users diagnosed in 2007-2011 and 395 patients diagnosed in 2001-2003, the median OS times were 17 and 11 months, respectively"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study found a median overall survival of 13 months for all CMML patients.  In a matched cohort analysis, patients receiving hypomethylating agents (HMAs) had a median OS of 17 months compared to 11 months for those not receiving HMAs, representing a 28% reduction in the risk of death.",
    "has_efficacy_data": true
  },
  {
    "pmid": "28370097",
    "citation": "Ana Alfonso et al. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.. American journal of hematology (2017 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28370097/",
    "drug": "azacitidine",
    "complete_response": 41.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 75.0,
    "progression_free_survival_median": 14.0,
    "overall_survival_median": 24.0,
    "total_patients": 151,
    "cmml_patients": 151,
    "supporting_quotes": [
      "With a median follow-up of 17 months, overall response rate (ORR) was 75%, with 41% achieving complete response (CR).",
      "Median overall survival (OS) was 24 months (95%CI: 20-28) and event-free survival 14 months (95%CI: 11-17)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Hypomethylating agents showed an overall response rate of 75%, with a 41% complete response rate. Median overall survival was 24 months and median progression-free survival was 14 months.  Decitabine showed a significantly higher complete response rate (58.3%) compared to azacitidine (20.6%). Outcomes after HMA failure were poor, with a median OS of 7 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "28368509",
    "citation": "M T Voso et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study.. Annals of oncology : official journal of the European Society for Medical Oncology (2017 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/28368509/",
    "drug": "azacitidine",
    "complete_response": 24.0,
    "partial_response": 14.0,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 97,
    "cmml_patients": 8,
    "supporting_quotes": [
      "After a median of four cycles (range 1-11): 24% of patients achieved complete remission, 14% partial remission, 8% hematologic improvement, 32% had stable and 22% progressive disease.",
      "We conducted a phase II multicenter study to prospectively evaluate the feasibility of HSCT after treatment with AZA in 70 patients with a myelodysplastic syndrome (MDS), 19 with acute myeloid leukemia (AML), and 8 with chronic myelomonocytic leukemia (CMML)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports complete remission (CR) in 24% and partial remission (PR) in 14% of patients after a median of four cycles of azacitidine.  Overall response rate is not explicitly provided. No survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "27353473",
    "citation": "Colombe Saillard et al. Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.. Hematological oncology (2017 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27353473/",
    "drug": "azacitidine",
    "complete_response": 100.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 100.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 1,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Treatment with 5-azacytidine led to the complete remission of both diseases."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In this single case report, treatment with 5-azacytidine resulted in a complete remission of both AITL and CMML.",
    "has_efficacy_data": true
  },
  {
    "pmid": "27185207",
    "citation": "Mrinal M Patnaik et al. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.. American journal of hematology (2016 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/27185207/",
    "drug": "azacitidine",
    "complete_response": 7.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 35.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "Hypomethylating agents such as 5-azacitidine and decitabine are commonly used, with overall response rates of ∼30-40% and complete remission rates of ∼7-17%",
      "The GFM model segregates patients into 3 groups ... with respective median survivals of 56 (low), 27.4 (intermediate), and 9.2 (high) months.",
      "The MMM is based on ... This model stratifies patients into four groups; high (≥3 risk factors), intermediate-2 (2 risk factors), intermediate-1 (1 risk factor) and low (no risk factors), with median survivals of 16, 31, 59, and 97 months, respectively."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports overall response rates of 30-40% and complete remission rates of 7-17% for hypomethylating agents.  The GFM and MMM prognostic models provide overall survival median values ranging from 9.2 to 97 months depending on risk factors.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26922775",
    "citation": "Jean-Baptiste Fraison et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.. Leukemia research (2016 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26922775/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 55.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 22,
    "cmml_patients": null,
    "supporting_quotes": [
      "Response of AID to Azacitidine was observed in 19 patients (86%).",
      "Hematologic response was seen in 55% of the patients."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall hematologic response rate of 55% to Azacitidine in patients with autoimmune disorders associated with MDS/CMML.  No data on complete response, partial response, marrow complete response, progression-free survival, or overall survival was provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26860635",
    "citation": "Marjan Cruijsen et al. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2016 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26860635/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 30,
    "cmml_patients": 2,
    "supporting_quotes": [
      "Thirty patients were enrolled, including 11 with MDS, 2 with CMML, and 17 with AML.",
      "At a median follow-up of 443 days, the overall survival was 53%, relapse incidence was 27%, and nonrelapse mortality was 27%."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports overall survival of 53% at a median follow-up of 443 days (approximately 14.8 months), relapse incidence of 27%, and non-relapse mortality of 27%.  No response rates (CR, PR, mCR, ORR) or PFS data were provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "26350487",
    "citation": "Arsène Mekinian et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.. Rheumatology (Oxford, England) (2016 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26350487/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 83.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 123,
    "cmml_patients": null,
    "supporting_quotes": [
      "In this study, 123 patients with MDS and SIADs were analysed.",
      "One hundred and eighteen (96%) SIAD patients were treated (91% with steroids), with an 83% response to first-line treatment, including 80% for steroids alone."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 83% to first-line treatment for systemic inflammatory and autoimmune diseases (SIADs) associated with myelodysplastic syndromes (MDS).  The response rate to steroids alone was 80%.  No overall survival or progression-free survival data is provided for CMML treatment efficacy.",
    "has_efficacy_data": true
  },
  {
    "pmid": "25735917",
    "citation": "Stéphanie Harel et al. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.. Leukemia research (2015 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25735917/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": 8.33,
    "overall_response_rate": 19.4,
    "progression_free_survival_median": null,
    "overall_survival_median": 7.3,
    "total_patients": 36,
    "cmml_patients": null,
    "supporting_quotes": [
      "Seven (19.4%) patients were responders including 3 marrow CR (mCR), 2 stable disease (SD) with HI-E, 1 SD with HI-N and HI-P and 1 SD with HI-N.",
      "Median OS from onset of decitabine was 7.3 months",
      "Treatment with decitabine after azacitidine failure yielded modest ORR (19.4%) with short response duration and poor OS."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Decitabine treatment after azacitidine failure in high-risk MDS and CMML patients showed a modest overall response rate (ORR) of 19.4%, with a median overall survival (OS) of 7.3 months.  Responses were short-lived.  The mCR rate was 8.33% (3/36).",
    "has_efficacy_data": true
  },
  {
    "pmid": "25555161",
    "citation": "M M Patnaik et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome.. Blood cancer journal (2015 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25555161/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 40.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 261,
    "cmml_patients": 261,
    "supporting_quotes": [
      "'In multivariable analysis, lower HB (P=0.01), higher circulating blast % (P=0.002), ASXL1 (P=0.0007) and SRSF2 mutations (P=0.008) and Mayo-French cytogenetic stratification (P=0.04) negatively impacted survival.'",
      "'Seventy-five (29%) patients received hypomethylating agents (HMA), with the median number of cycles being 5, and the median duration of therapy being 5 months.'",
      "The over-all response rate was 40% for azacitidine and 30% for decitabine.'",
      "'Fifty-three (24%) patients underwent an allogeneic hematopoietic stem cell transplant (AHSCT), with a response rate of 56% and a non-relapse mortality of 19%.'"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 40% for azacitidine and 30% for decitabine in CMML patients treated with hypomethylating agents.  Allogeneic hematopoietic stem cell transplant showed a 56% response rate.  No median survival times were provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "25444072",
    "citation": "Y Beguin et al. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.. Acta clinica Belgica (2015 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/25444072/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 41.4,
    "progression_free_survival_median": null,
    "overall_survival_median": 40.8,
    "total_patients": 49,
    "cmml_patients": 2,
    "supporting_quotes": [
      "Among MDS and CMML patients (n = 29), 41·4% had CR, PR, or HI, 41·4% had SD, and 17·2% had TF.",
      "Median (95% confidence interval) OS was 490 (326-555) days; 1-year OS estimate was 0·571 (0·422-0·696)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In a real-life setting, azacitidine showed an overall response rate of 41.4% among MDS and CMML patients.  Median overall survival was 40.8 months (490 days).",
    "has_efficacy_data": true
  },
  {
    "pmid": "24836762",
    "citation": "Cecile Bally et al. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.. Leukemia research (2014 Jul)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24836762/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 21.2,
    "total_patients": 62,
    "cmml_patients": null,
    "supporting_quotes": [
      "TP53 mutations had no significant impact on response or complete response to AZA (p=0.60 and p=0.26, respectively).",
      "By univariate analysis, OS was negatively influenced by the presence of TP53 mutation (median OS 12.4 months versus 23.7 months, p<10(-4)), abnormal cytogenetics (median OS 14.4 months vs 33 months, p=0.02) complex cytogenetics (median OS 12.7 months versus 23.7 months, p=0.0005), and a diagnosis of AML (median 14.5 months vs 21.2 months for MDS or CMML, p=0.02)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study found no significant impact of TP53 mutations on response to azacitidine.  Univariate analysis showed that overall survival (OS) was negatively impacted by TP53 mutations (median OS 12.4 months vs 23.7 months), with a median OS of 21.2 months observed for patients with MDS or CMML.",
    "has_efficacy_data": true
  },
  {
    "pmid": "24678397",
    "citation": "Andrea Tendas et al. Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach.. Mediterranean journal of hematology and infectious diseases (2014)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24678397/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 70.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 10,
    "cmml_patients": 10,
    "supporting_quotes": [
      "The overall response rate of 70% was achieved without remarkable toxicities",
      "At our institution, between 2010 and 2012, we have treated with azacitidine 10 CMML patients",
      "With a median follow-up of 12,5 (2-27) months, 6 patients are alive, and 4 of them continue to receive the treatment; the median survival from the start of therapy was not reached."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine demonstrated a 70% overall response rate in 10 CMML patients.  Median survival was not reached at a median follow-up of 12.5 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "24522248",
    "citation": "Lisa Pleyer et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival.. Leukemia research (2014 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24522248/",
    "drug": "azacitidine",
    "complete_response": 22.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 70.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 27.7,
    "total_patients": 48,
    "cmml_patients": 48,
    "supporting_quotes": [
      "Overall response rates were high (70% according to IWG-criteria, including 22% complete responses).",
      "Matched-pair analyses revealed a trend for higher two-year-survival for azacitidine as compared to best supportive care (62% vs. 41%, p=0.067) and longer OS for azacitidine first-line vs. hydroxyurea first-line (p=0.072, median OS 27.7 vs. 6.2 months)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine showed a 70% overall response rate, including a 22% complete response rate. Matched-pair analyses suggested a trend towards improved two-year survival and longer overall survival (median 27.7 months) compared to other treatments.",
    "has_efficacy_data": true
  },
  {
    "pmid": "23963888",
    "citation": "Sameer A Parikh et al. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management.. American journal of hematology (2013 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23963888/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 18.5,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "The Mayo prognostic model classified CMML patients into three risk groups based on: increased absolute monocyte count, presence of circulating blasts, hemoglobin <10 gm/dL and platelets <100 × 10⁹/L. The median survival was 32 months, 18.5 months and 10 months in the low, intermediate, and high-risk groups, respectively.",
      "After a median follow-up of 2.5 years, survival ranged from not reached in the low-risk group to 14.4 months in the high-risk group."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The Mayo model shows median survival times of 32, 18.5, and 10 months for low, intermediate, and high-risk CMML patients, respectively.  The GFM model shows survival ranging from not reached to 14.4 months in high-risk patients after a 2.5 year follow-up.  No response rates are provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "23415110",
    "citation": "Lionel Adès et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.. Leukemia research (2013 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23415110/",
    "drug": "azacitidine",
    "complete_response": 17.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 43.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 29.0,
    "total_patients": 76,
    "cmml_patients": 76,
    "supporting_quotes": [
      "Thirty-three patients (43%) achieved a response according to IWG 2006 criteria, including 13 complete remissions (17%).",
      "Median survival was 29 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine showed an overall response rate of 43% in 76 CMML patients, with a 17% complete remission rate. Median overall survival was 29 months.  The study notes that efficacy in advanced CMML needs further confirmation.",
    "has_efficacy_data": true
  },
  {
    "pmid": "23262795",
    "citation": "Jun Ho Yi et al. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.. Annals of hematology (2013 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/23262795/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 26.4,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 61,
    "cmml_patients": null,
    "supporting_quotes": [
      "Best response was noted in 14 patients (26.4 %) out of 53 evaluated patients including 12 CR and two PR with median follow-up of 21.6 months",
      "A total of 61 MDS/CMML patients treated with decitabine were evaluated"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reported an overall response rate of 26.4% (14/53 patients) to decitabine treatment in MDS/CMML patients.  The response included 12 complete responses and 2 partial responses.  Median follow-up was 21.6 months.  No specific survival data is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "22937326",
    "citation": "Peter Rohon et al. Treatment of chronic myelomonocytic leukemia with 5-azacytidine: case reports.. Case reports in hematology (2012)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22937326/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": 33.3,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 3,
    "cmml_patients": 3,
    "supporting_quotes": [
      "In this paper our experience with 3 CMML patients treated with AZA is described.",
      "In one patient transfusion independency was observed after 4 treatment cycles; in one case a partial response was recorded, but a progression to acute myeloid leukemia (AML) after 13 AZA cycles has appeared."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 90,
    "efficacy_summary": "Out of 3 CMML patients treated with 5-azacytidine, one achieved transfusion independence, and one had a partial response.  No overall response rate, progression-free survival, or overall survival data was provided. One patient progressed to AML.",
    "has_efficacy_data": true
  },
  {
    "pmid": "22607959",
    "citation": "Michael Thorpe et al. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review.. Leukemia research (2012 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22607959/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 60.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 20,
    "total_patients": 10,
    "cmml_patients": 10,
    "supporting_quotes": [
      "We present the outcome of ten patients diagnosed with CMML and treated with AZA in our institutions between 2005 and 2010.",
      "The overall response rate was 60%.",
      "Responses were obtained in 2/3 of the patients with proliferative CMML.",
      "The median survival from start of therapy was 20 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 60% in 10 CMML patients treated with AZA.  Median overall survival was 20 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "22280532",
    "citation": "Massimo Breccia et al. 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.. Leukemia & lymphoma (2012 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/22280532/",
    "drug": "azacitidine",
    "complete_response": 18.0,
    "partial_response": 18.0,
    "marrow_complete_response": null,
    "overall_response_rate": 36.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 16.4,
    "total_patients": 38,
    "cmml_patients": 4,
    "supporting_quotes": [
      "after the first four cycles we detected complete remission in seven patients (CR, 18%), improvement of bone marrow dysplasia and reduction of blast percentage in seven patients (partial response, 18%), stable disease in 20 patients (53%) and progression to acute leukemia in four patients (10%)",
      "Median overall survival for all patients treated was 16.4 months",
      "four patients with chronic myelomonocytic leukemia type 2 (CMML-2)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In this study of 38 MDS patients (including 4 with CMML), azacitidine treatment resulted in a 18% complete response rate and a 18% partial response rate, leading to a 36% overall response rate. Median overall survival was 16.4 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "21981697",
    "citation": "Lieke H van der Helm et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.. British journal of haematology (2011 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21981697/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 50.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 13.0,
    "total_patients": 90,
    "cmml_patients": null,
    "supporting_quotes": [
      "The overall response rate (complete/partial/haematological improvement) was 57% in low risk MDS, 53% in high risk MDS, 50% in CMML, and 39% in AML patients.",
      "Median overall survival (OS) was 13·0 (9·8-16·2) months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine demonstrated an overall response rate of 50% in CMML patients, with a median overall survival of 13 months.  Specific response rates (CR, PR, mCR) are not provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "21828134",
    "citation": "Thorsten Braun et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.. Blood (2011 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21828134/",
    "drug": "azacitidine",
    "complete_response": 10.0,
    "partial_response": null,
    "marrow_complete_response": 21.0,
    "overall_response_rate": 38.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 39,
    "cmml_patients": 39,
    "supporting_quotes": [
      "Overall response rate was 38% with 4 complete responses (10%), 8 marrow responses (21%), and 3 stable diseases with hematologic improvement (8%).",
      "With a median follow-up of 23 months, overall survival was 48% at 2 years."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 38% to decitabine in 39 patients with advanced CMML.  Complete responses were observed in 10% of patients and marrow responses in 21%. Overall survival at 2 years was 48%.",
    "has_efficacy_data": true
  },
  {
    "pmid": "21656746",
    "citation": "Rubens Costa et al. Activity of azacitidine in chronic myelomonocytic leukemia.. Cancer (2011 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21656746/",
    "drug": "azacitidine",
    "complete_response": 11.0,
    "partial_response": 3.0,
    "marrow_complete_response": null,
    "overall_response_rate": 39.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 12.0,
    "total_patients": 38,
    "cmml_patients": 38,
    "supporting_quotes": [
      "The overall response rate was 39% (14 of 36); complete response (CR) rate was 11% (4 of 36); partial response (PR) rate was 3% (1 of 36); hematologic improvement (HI) was 25% (9 of 36).",
      "The median overall survival was 12 months.",
      "There was a statistically significant overall survival advantage in responders compared with nonresponders: 15.5 months versus 9 months, respectively (P = .04)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Azacitidine demonstrated an overall response rate of 39% in CMML patients, with 11% achieving complete response and 3% partial response. Median overall survival was 12 months, significantly longer (15.5 months) for responders compared to non-responders (9 months).",
    "has_efficacy_data": true
  },
  {
    "pmid": "21625315",
    "citation": "M Greco et al. 5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature.. Mediterranean journal of hematology and infectious diseases (2011)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21625315/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": 66.7,
    "marrow_complete_response": null,
    "overall_response_rate": 66.7,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 3,
    "cmml_patients": 3,
    "supporting_quotes": [
      "Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Two out of three CMML patients achieved a partial response after four cycles of azacitidine treatment.  These patients remained in partial response for at least 29 and 30 cycles.",
    "has_efficacy_data": true
  },
  {
    "pmid": "21576646",
    "citation": "Guillermo Garcia-Manero et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21576646/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 35.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 41,
    "cmml_patients": 4,
    "supporting_quotes": [
      "Overall response rate (i.e., complete remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in previously untreated patients.",
      "Overall, 41 patients received SC and oral azacitidine (MDSs, n = 29; CMML, n = 4; AML, n = 8)."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study reports an overall response rate of 35% in previously treated patients and 73% in previously untreated patients with MDS and CMML.  No data on complete response, partial response, marrow complete response, progression-free survival, or overall survival was provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "21387357",
    "citation": "Murat Ozbalak et al. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.. Hematological oncology (2012 Jun)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/21387357/",
    "drug": "azacitidine",
    "complete_response": 12.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 36.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 25,
    "cmml_patients": null,
    "supporting_quotes": [
      "Complete response (CR) rate was observed in three of the 25 'real life' patients (12%) with a median duration of CR of 5 months (4-6 months).",
      "Seven patients (28%) had mono- or bi-lineage haematologic improvement and 15 patients (60%) showed neither morphologic nor haematologic response."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed a 12% complete response rate and a 28% rate of mono- or bi-lineage hematologic improvement among 25 patients with MDS, CMML, or AML treated with azacitidine. The overall response rate is calculated as 36% (12% CR + 28% hematologic improvement). No overall survival or progression-free survival data was explicitly provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "20507806",
    "citation": "R Edlin et al. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.. Health technology assessment (Winchester, England) (2010 May)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/20507806/",
    "drug": "azacitidine",
    "complete_response": 17.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 24.5,
    "total_patients": 358,
    "cmml_patients": null,
    "supporting_quotes": [
      "the median overall survival was 24.5 months on aza, compared with 15.0 months in the CCR group (p = 0.0001)",
      "the response rates were low (complete remission 17% aza versus 8% CCR);",
      "the median time to transformation to AML was greater in the aza group (17.8 versus 11.5 months; p < 0.0001)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Azacitidine demonstrated improved overall survival (24.5 months vs 15.0 months in the control group) and delayed time to AML transformation (17.8 months vs 11.5 months). Complete response rates were low (17% in the azacitidine group vs 8% in the control group).  The number of CMML patients was not explicitly stated.",
    "has_efficacy_data": true
  },
  {
    "pmid": "20451404",
    "citation": "John F Seymour et al. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.. Critical reviews in oncology/hematology (2010 Dec)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/20451404/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 87,
    "cmml_patients": null,
    "supporting_quotes": [
      "This analysis compared azacitidine (AZA) to conventional care regimens (CCR) and their associated overall survival (OS) and tolerability in the subset of 87 elderly (≥ 75 years) patients with higher-risk MDS (FAB: RAEB, RAEB-t, CMML and IPSS: Int-2 or High) from the AZA-001 trial.",
      "AZA significantly improved OS vs CCR (HR: 0.48 [95%CI: 0.26, 0.89]; p=0.0193) and 2-year OS rates were 55% vs 15% (p<0.001), respectively."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study shows a significant improvement in overall survival (OS) for azacitidine compared to conventional care regimens (CCR) in elderly patients with higher-risk MDS, including a subset of CMML patients.  The exact number of CMML patients is not specified, and no response rates were reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "20064151",
    "citation": "Bart L Scott et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.. British journal of haematology (2010 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/20064151/",
    "drug": "azacitidine",
    "complete_response": 28.1,
    "partial_response": 6.3,
    "marrow_complete_response": 31.3,
    "overall_response_rate": 72.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 32,
    "cmml_patients": null,
    "supporting_quotes": [
      "At 3 months, nine patients had achieved complete response (CR), two had partial response, 10 had marrow CRs, seven had stable disease, two patients had haematological improvement without marrow response and two patients had disease progression.",
      "The overall response rate was 72%; median duration of response was not reached at 2 years."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 72% at 3 months, with 28.1% achieving complete response, 6.3% partial response, and 31.3% marrow complete response.  Median duration of response was not reached at 2 years.  Specific numbers for CMML patients are not provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "19638460",
    "citation": "Maria Teresa Voso et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.. Clinical cancer research : an official journal of the American Association for Cancer Research (2009 Aug)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/19638460/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 30.7,
    "progression_free_survival_median": null,
    "overall_survival_median": 14.4,
    "total_patients": 62,
    "cmml_patients": 4,
    "supporting_quotes": [
      "Of 26 patients who completed eight cycles, 30.7% obtained complete or partial remission, 15.4% had a major hematologic improvement, whereas 38.5% showed stable disease.",
      "The median overall survival was 14.4 months.",
      "We enrolled 62 patients with MDS (refractory anemia with excess blasts, 39 patients; refractory anemia with excess blasts in transformation, 19 patients; and chronic myelomanocytic leukemia (CMML), 4 patients)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "In a study of 62 patients with higher-risk MDS (including 4 with CMML), the combination of 5-AZA and VPA showed a 30.7% overall response rate (complete or partial remission) among 26 patients completing eight cycles. Median overall survival was 14.4 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "18179966",
    "citation": "Elizabeth A Griffiths et al. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.. Seminars in hematology (2008 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/18179966/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 30.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": null,
    "cmml_patients": null,
    "supporting_quotes": [
      "These agents were developed based upon an understanding of the importance of epigenetic changes in malignancy, and they have been evaluated in randomized clinical trials, which demonstrate response rates between 20% and 40% in patients for whom no previous standard of care was available."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 80,
    "efficacy_summary": "The abstract reports overall response rates between 20% and 40% for 5-azacitidine and 5-aza-2'-deoxyazacytidine in clinical trials for MDS and CMML patients without prior standard treatment.  No specific data for CMML alone or on survival is provided.",
    "has_efficacy_data": true
  },
  {
    "pmid": "17881052",
    "citation": "P W Wijermans et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).. Leukemia research (2008 Apr)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17881052/",
    "drug": "azacitidine",
    "complete_response": 14.0,
    "partial_response": 11.0,
    "marrow_complete_response": null,
    "overall_response_rate": 25.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 31,
    "cmml_patients": 31,
    "supporting_quotes": [
      "The ORR was 25% (14% CR+11% PR)",
      "A total of 31 patients diagnosed with CMML are included in this review"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Decitabine demonstrated an overall response rate of 25% in 31 CMML patients, with 14% achieving complete response and 11% achieving partial response.  No survival data was reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "17219444",
    "citation": "Ahmed Aribi et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.. Cancer (2007 Feb)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/17219444/",
    "drug": "azacitidine",
    "complete_response": 58.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 69.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 19,
    "total_patients": 19,
    "cmml_patients": 19,
    "supporting_quotes": [
      "Overall, 11 patients (58%) achieved complete response (CR) and 2 (11%) had hematologic improvement (HI), for an overall response rate of 69% according to the modified International Working Group (IWG) criteria.",
      "Median survival was 19 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "Decitabine demonstrated a 69% overall response rate in 19 CMML patients, with 58% achieving complete response. Median survival was 19 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "16955510",
    "citation": "Alfonso Quintas-Cardama et al. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.. Cancer (2006 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/16955510/",
    "drug": "azacitidine",
    "complete_response": 11.0,
    "partial_response": 16.0,
    "marrow_complete_response": null,
    "overall_response_rate": 41.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 44,
    "cmml_patients": 32,
    "supporting_quotes": [
      "Overall, 5 (11%) patients achieved complete response (CR), 7 (16%) had a partial response (PR), and 6 (14%) had hematologic improvement (HI), for an overall response rate of 41%.",
      "Adults with a diagnosis of MDS (n = 12) and CMML (n = 32) received 9-NC 2 mg/m(2) orally daily 5 days a week, every 4 to 6 weeks."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 100,
    "efficacy_summary": "The study showed an overall response rate of 41% in patients with MDS and CMML treated with 9-NC, with 11% achieving complete response and 16% achieving partial response.  No survival data was reported.",
    "has_efficacy_data": true
  },
  {
    "pmid": "16882708",
    "citation": "Hagop Kantarjian et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.. Blood (2007 Jan)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/16882708/",
    "drug": "azacitidine",
    "complete_response": 34.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 73.0,
    "progression_free_survival_median": null,
    "overall_survival_median": null,
    "total_patients": 95,
    "cmml_patients": 18,
    "supporting_quotes": [
      "Overall, 32 patients (34%) achieved a complete response (CR), and 69 (73%) had an objective response by the new modified International Working Group criteria.",
      "The 5-day intravenous schedule, which had the highest dose-intensity, was selected as optimal; the CR rate in that arm was 39%, compared with 21% in the 5-day subcutaneous arm and 24% in the 10-day intravenous arm (P < .05).",
      "Ninety-five patients were treated (77 with MDS, and 18 with CMML)"
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed an overall response rate of 73% with a complete response rate of 34% across all treatment arms.  The 5-day intravenous schedule demonstrated superior efficacy with a 39% complete response rate.",
    "has_efficacy_data": true
  },
  {
    "pmid": "12599231",
    "citation": "Marcos de Lima et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.. Cancer (2003 Mar)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/12599231/",
    "drug": "azacitidine",
    "complete_response": null,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 26.0,
    "progression_free_survival_median": 8.9,
    "overall_survival_median": 17.2,
    "total_patients": 23,
    "cmml_patients": 1,
    "supporting_quotes": [
      "Twenty-one patients were engrafted and achieved disease remission.",
      "At a median of 3.3 years posttransplantation, 26% of patients (40% of patients with AML) were alive and disease free.",
      "The median survival for the group was 17.2 months, and the disease free survival for the group was 8.9 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "The study showed a 26% overall response rate, with a median overall survival of 17.2 months and a median disease-free survival of 8.9 months. Only one patient with CMML participated in the study.",
    "has_efficacy_data": true
  },
  {
    "pmid": "9922042",
    "citation": "M Beran et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.. Leukemia & lymphoma (1998 Nov)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/9922042/",
    "drug": "azacitidine",
    "complete_response": 27.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": null,
    "progression_free_survival_median": null,
    "overall_survival_median": 10.5,
    "total_patients": 60,
    "cmml_patients": 30,
    "supporting_quotes": [
      "Nineteen patients (31%) achieved a complete response (CR). A CR was achieved in 11 of 30 patients with MDS (37%) and in eight of 30 with CMML (27%).",
      "With a median follow-up duration of 31 months, the 12 month survival rate was 38%, median survival time 10.5 months, and median remission duration 7.5 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Topotecan showed a 27% complete response rate in CMML patients.  Median overall survival was 10.5 months.",
    "has_efficacy_data": true
  },
  {
    "pmid": "8839838",
    "citation": "M Beran et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.. Blood (1996 Oct)",
    "url": "https://pubmed.ncbi.nlm.nih.gov/8839838/",
    "drug": "azacitidine",
    "complete_response": 28.0,
    "partial_response": null,
    "marrow_complete_response": null,
    "overall_response_rate": 41.0,
    "progression_free_survival_median": null,
    "overall_survival_median": 10.5,
    "total_patients": 47,
    "cmml_patients": 25,
    "supporting_quotes": [
      "Thirteen patients (28%) achieved a complete response (CR) and six (13%) had hematologic improvement.",
      "A CR was achieved in six of 22 patients with MDS (27%) and in seven of 25 with CMML (28%).",
      "With a median follow-up duration of 8 months, the 12-month survival rate was 38%, median survival time 10.5 months, and median remission duration 7.5 months."
    ],
    "data_source_location": "abstract",
    "extraction_confidence": 95,
    "efficacy_summary": "Topotecan showed a 28% complete response rate overall, with similar rates in MDS and CMML patients.  The median overall survival was 10.5 months.",
    "has_efficacy_data": true
  }
]